Vor Biopharma Inc. (VOR) Income Statement
VOR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsVOR revenue and net income
VOR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VOR quarterly EPS vs estimates
Vor Biopharma beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.81).
VOR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $3.5M | $3.5M | $9.0M | $4.5M | $1.4M | $91,000 | $20,000 |
| Gross profit | — | −$3.5M | −$3.5M | −$9.0M | −$4.5M | −$1.4M | −$91,000 | −$20,000 |
| Research & development | $321.5M | $93.3M | $94.3M | $64.5M | $47.5M | $31.6M | $6.2M | $2.4M |
| Sales, general & admin | $50.1M | $27.9M | $31.7M | $28.9M | $21.5M | $11.7M | $4.2M | $427,000 |
| Total operating expenses | $371.6M | $121.2M | $122.5M | $84.5M | $69.0M | $43.4M | $10.3M | $2.9M |
| Operating income | −$371.6M | −$121.2M | −$126.0M | −$93.4M | −$69.0M | −$43.4M | −$10.4M | −$2.9M |
| Interest income | $5.9M | $4.3M | $7.1M | $1.3M | $119,000 | $29,000 | $154,000 | $0 |
| Interest expense | — | — | — | $1.3M | $1.6M | $0 | $608,000 | $1.0M |
| Income before taxes | −$696.0M | −$116.9M | −$117.9M | −$92.1M | −$68.9M | −$43.3M | −$10.8M | −$4.2M |
| Income taxes | — | — | — | −$1.3M | −$119,000 | $427,703 | $608,000 | −$289,000 |
| Net income | −$696.0M | −$116.9M | −$117.9M | −$92.1M | −$68.9M | −$43.3M | −$10.8M | −$4.2M |
| EBITDA | −$693.1M | −$113.4M | −$114.4M | −$89.6M | −$67.5M | −$42.8M | −$10.1M | −$2.8M |
| EPS (diluted) | −$70.50 | −$25.64 | −$27.79 | −$36.92 | −$33.88 | −$233.56 | −$8.08 | −$1.33 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3.7M | $0 | $0 | $0 | $12.2M | $0 |
| Cost of revenue | — | $28,000 | $23,000 | — | $2.1M | $825,000 | $865,000 | $900,000 | $900,000 | $943,000 | $892,000 | $2.1M |
| Gross profit | — | −$28,000 | −$23,000 | — | −$2.1M | −$825,000 | −$865,000 | −$900,000 | −$900,000 | −$943,000 | −$892,000 | −$2.1M |
| Research & development | $25.9M | $17.6M | $19.2M | $14.1M | $261.5M | $26.7M | $25.3M | $21.8M | $21.8M | $24.3M | $20.9M | $27.6M |
| Sales, general & admin | $21.9M | $17.5M | $16.8M | $14.4M | $2.4M | $6.6M | $6.0M | $6.7M | $7.2M | $8.0M | $7.2M | $7.7M |
| Total operating expenses | $47.9M | $35.1M | $36.0M | $28.1M | $274.3M | $33.3M | $30.4M | $28.5M | $28.1M | $31.4M | $27.2M | $35.3M |
| Operating income | −$47.9M | −$35.2M | −$36.0M | −$28.1M | −$274.3M | −$33.3M | −$31.3M | −$28.5M | −$29.0M | −$32.3M | −$28.1M | −$35.3M |
| Interest income | $4.3M | $3.9M | $2.8M | $1.7M | $537,000 | $805,000 | $599,000 | $954,000 | $1.2M | $1.5M | $1.9M | $2.1M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.0M | — |
| Income before taxes | −$62.8M | −$219.6M | $1.72B | −$812.7M | −$1.57B | −$32.5M | −$30.7M | −$27.6M | −$27.8M | −$30.8M | −$26.3M | −$33.2M |
| Income taxes | — | — | — | — | — | — | −$899,724 | — | $899,724 | $899,724 | $565,000 | $1.4M |
| Net income | −$62.8M | −$219.6M | $1.72B | −$812.7M | −$1.57B | −$32.5M | −$30.7M | −$27.6M | −$27.8M | −$30.8M | −$26.3M | −$33.2M |
| EBITDA | −$47.8M | −$219.6M | $1.72B | −$812.7M | −$241.5M | −$31.7M | −$29.8M | −$26.7M | −$27.0M | −$29.9M | −$25.4M | −$32.3M |
| EPS (diluted) | −$0.80 | −$0.73 | $307.53 | −$121.63 | −$251.20 | −$5.20 | −$0.44 | −$8.00 | −$8.20 | −$9.00 | −$0.39 | −$9.80 |
| Gross margin | — | — | — | — | — | — | −23.5% | — | — | — | −7.3% | — |
| Operating margin | — | — | — | — | — | — | −849.5% | — | — | — | −230.0% | — |
| Net margin | — | — | — | — | — | — | −833.2% | — | — | — | −214.8% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VOR's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VOR financial results
Vor Biopharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $696.0 million. Diluted earnings per share came to −$70.50.
See the VOR stock overview for the latest quote and news, or the VOR chart for price history and technical indicators.
VOR income statement FAQ
Does Vor Biopharma have revenue?
Vor Biopharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Vor Biopharma profitable?
No. Vor Biopharma reported a net loss of $696.0 million in fiscal 2025.
How much does Vor Biopharma spend on research and development?
Vor Biopharma spent $321.5 million on research and development in fiscal 2025.
What are Vor Biopharma's earnings per share?
Vor Biopharma earned $-70.50 per diluted share in fiscal 2025, compared with $-25.64 a year earlier.
When will Vor Biopharma report its next earnings?
Vor Biopharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Vor Biopharma's fiscal year end?
Vor Biopharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.